Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT03511118 · Duke University

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

What this study is about

Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying.

View original scientific description

Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by breastfed infants.

Interventions

DRUG

Tranexamic acid (TXA)

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

labetalol

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

metformin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

nifedipine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

clindamycin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

oxycodone

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

azithromycin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

escitalopram

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

sertraline

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

ondansetron

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Ciprofloxacin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Doxycycline

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Levofloxacin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Methylphenidate

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Sumatriptan

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Citalopram

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Cyclobenzaprine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Furosemide

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Gabapentin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Hydrochlorothiazide

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Hydroxyurea

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Rosuvastatin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Topiramate

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Trazodone

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Valganciclovir

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Venlafaxine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Verapamil

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Remdesivir

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Anakinra

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Tocilizumab

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Fluvoxamine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Amoxicillin

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Bupropion

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Duloxetine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Hydrocodone

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Levetiracetam

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Paroxetine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

DRUG

Buprenorphine

Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Primary outcome measures

M/P ratio

Time frame: Until the infant becomes 180 days of age

Characterize the pharmacokinetics using maternal milk/plasma exposure ratio is calculated by dividing the BMS01 drug of interest breastmilk concentration by the BMS01 drug of interest in maternal plasma concentration.

DID

Time frame: Until the infant becomes 180 days of age

Pharmacokinetics is characterized by estimated daily infant dose-daily infant dose which estimates the quantity of drug delivered to an infant via breastmilk in a given day.

RID

Time frame: Until the infant becomes 180 days of age

Pharmacokinetics is characterized by relative infant dose is a method of relating the potential dose of the drug delivered to the infant to the typical therapeutic dose given to the mother.

I/M ratio

Time frame: Until the infant becomes 180 days of age

Pharmacokinetics is characterized using infant maternal/exposure ratio. IM ratio is calculated using the average infant plasma concentration of the BMS01 drug of interest and historical value of clearance in infants.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Lactating women who are receiving at least one DOI per SOC who are ≤180 days postpartum, and their infants (≤180 days of age) who receive maternal breastmilk.
  • Informed consent/HIPAA obtained, according to local IRB/REB/IEC guidelines, prior to any study-related procedures. Lactating women who are not legal adults and their breastfed infants may be enrolled if they assent to participate in the study and consent is obtained from their legal guardian according to local IRB/REB/IEC guidelines.

Exclusion criteria

  • Any concomitant condition which, in the opinion of the physicians providing patient care or the principal investigator conducting the study, would preclude a subject's participation in the study.
  • Known pregnancy during PK sampling.

Where

  • La Jolla, California
  • Loma Linda, California
  • Chicago, Illinois
  • Indianapolis, Indiana
  • Iowa City, Iowa
  • Minneapolis, Minnesota
  • Albuquerque, New Mexico
  • Chapel Hill, North Carolina
  • Durham, North Carolina
  • Portland, Oregon
  • Philadelphia, Pennsylvania
  • Pittsburgh, Pennsylvania

And 6 more locations — see the full list below.

Collaborators

The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Related conditions & keywords

Lactating Women on Select DOIBreastfed Infants of Mothers on Select DOI

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Jul 29, 2026 · Source of record for eligibility and locations

📊
1 of 1600 participants interested
0% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

La Jolla

California

Location available
RECRUITING

Loma Linda

California

Location available
COMPLETED

Chicago

Illinois

Location available
RECRUITING

Chicago

Illinois

Location available
COMPLETED

Indianapolis

Indiana

Location available
ACTIVE_NOT_RECRUITING

Iowa City

Iowa

Location available
RECRUITING

Minneapolis

Minnesota

Location available
COMPLETED

Albuquerque

New Mexico

Location available
COMPLETED

Chapel Hill

North Carolina

Location available

And 11 more locations available.

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Osteogenesis Imperfecta Trials by City

Browse all osteogenesis imperfecta clinical trials in these cities — not just this study.

Looking for Lactating Women on Select DOI Treatment in La Jolla?

Join others in California exploring innovative treatment options through clinical research

Lactating Women on Select DOI Treatment Options in La Jolla, California

If you're searching for Lactating Women on Select DOI treatment in La Jolla, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in La Jolla, Loma Linda, Chicago and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Lactating Women on Select DOI. All study-related care is provided at no cost to participants.

Local Sites
3 locations in California
Now Enrolling
Up to 1600 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Lactating Women on Select DOI?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Lactating Women on Select DOI

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Lactating Women on Select DOI Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT03511118. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.